A detailed history of Aqr Capital Management LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 5,118 shares of MDGL stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,118
Previous 4,610 11.02%
Holding current value
$1.73 Million
Previous $1.29 Million 15.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$212.22 - $292.96 $107,807 - $148,823
508 Added 11.02%
5,118 $1.09 Million
Q2 2024

Aug 14, 2024

SELL
$193.33 - $291.99 $134,364 - $202,933
-695 Reduced 13.1%
4,610 $1.29 Million
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $138,466 - $228,849
-808 Reduced 13.22%
5,305 $1.42 Million
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $13,605 - $26,795
-113 Reduced 1.81%
6,113 $1.41 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $43,958 - $67,959
-301 Reduced 4.61%
6,226 $909,000
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $31,397 - $48,048
-154 Reduced 2.31%
6,527 $1.51 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $1.11 Million - $1.47 Million
4,796 Added 254.43%
6,681 $1.62 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $110,065 - $558,977
1,885 New
1,885 $547,000
Q1 2019

May 14, 2019

SELL
$103.48 - $143.84 $512,743 - $712,727
-4,955 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $197,690 - $449,616
-2,086 Reduced 29.63%
4,955 $559,000
Q3 2018

Nov 15, 2018

SELL
$207.3 - $300.31 $984,467 - $1.43 Million
-4,749 Reduced 40.28%
7,041 $1.51 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $614,580 - $1.9 Million
6,052 Added 105.47%
11,790 $3.3 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $535,642 - $855,191
5,738 New
5,738 $670,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.8B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.